title: Decreased in vitro osteoblast proliferation and low turnover bone disease in nonuremic proteinuric patients.
abstract: Patients with proteinuria, even those with normal glomerular filtration rate, often present abnormal bone histology. We evaluated bone histology and the in vitro proliferation of osteoblasts in samples obtained from 17 proteinuric patients with primary glomerulopathies. Histomorphometric analysis of bone biopsies was performed, and bone fragments were obtained for osteoblast culture, in which we evaluated cell proliferation. In comparison to controls, patients presented lower trabecular bone volume (20.9+/-14.5% vs 26.8+/-5.9%; P=0.0008); lower trabecular number (1.7+/-0.2/mm vs 2.0+/-0.3/mm; P=0.004); and greater trabecular separation (475.5+/-96.4 microm vs 368.3+/-86.2 microm, P=0.0002). We also found alterations in bone formation and resorption: lower osteoid volume (0.9+/-0.7% vs 2.0+/-1.4%; P=0.0022); lower osteoid thickness (6.4+/-2.8 microm vs 11.5+/-3.2 microm; P<0.0001); less mineralizing surface (4.6+/-3.1% vs 13.5+/-6.0%; P<0.0001); lower bone formation rate (0.03+/-0.04 microm(3)/microm(2)/day vs 0.09+/-0.05 microm(3)/microm(2)/day; P<0.0001); and greater osteoclast surface (0.35+/-0.6 vs 0.05+/-0.1%, P=0.0016). Mean in vitro osteoblast proliferation was lower in patients than in controls (910.2+/-437.1 vs 2261.0+/-1121.0 d.p.m./well, P=0.0016). Serum concentrations of 25-hydroxyvitamin-D(3) correlated negatively with proteinuria and positively with in vitro osteoblast proliferation. Our results demonstrate that nonuremic proteinuric glomerulonephritic patients present bone structure disorder, low bone formation and high bone resorption, as well as low osteoblast proliferation.
authors.affiliation: Renal Division, Department of Internal Medicine, University of São Paulo, São Paulo, Brazil. cristianebitencourt@uol.com.br
authors.forename: C B
authors.initials: CB
authors.lastname: Dias
authors.forename: L M
authors.initials: LM
authors.lastname: Dos Reis
authors.forename: V F
authors.initials: VF
authors.lastname: Caparbo
authors.forename: F G
authors.initials: FG
authors.lastname: Graciolli
authors.forename: R M A
authors.initials: RM
authors.lastname: Moysés
authors.forename: R T
authors.initials: RT
authors.lastname: Barros
authors.forename: V
authors.initials: V
authors.lastname: Jorgetti
authors.forename: V
authors.initials: V
authors.lastname: Woronik
mesh_terms: D000328:Adult; D001706:Biopsy; D001847:Bone Diseases / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D001862:Bone Resorption / Q000503:physiopathology; D001842:Bone and Bones / Q000378:metabolism / Q000473:pathology; D002112:Calcifediol / Q000097:blood; D049109:Cell Proliferation; D002478:Cells, Cultured; D005260:Female; D005919:Glomerular Filtration Rate / Q000502:physiology; D006801:Humans; D008297:Male; D016555:Matched-Pair Analysis; D008875:Middle Aged; D010006:Osteoblasts / Q000378:metabolism* / Q000473:pathology*; D010012:Osteogenesis / Q000502:physiology; D011507:Proteinuria / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology
chemical_list: D002112:Calcifediol